Researchers develop E. coli vaccine

Apr 14, 2009

A Michigan State University researcher has developed a working vaccine for a strain of E. coli that kills 2 million to 3 million children each year in the developing world.

Enterotoxigenic E. coli, which is responsible for 60 percent to 70 percent of all E. coli diarrheal disease, also causes health problems for U.S. troops serving overseas and is responsible for what is commonly called traveler's diarrhea.

A. Mahdi Saeed, professor of epidemiology and infectious disease in MSU's colleges of Veterinary Medicine and Human Medicine, has applied for a patent for his discovery and has made contact with pharmaceutical companies for commercial production. Negotiations with several firms are ongoing.

"This strain of E. coli is an international health challenge that has a huge impact on humanity," said Saeed, who has devoted four years to develop a working at MSU's National Food Safety and Toxicology Center. "By creating a vaccine, we can save untold lives. The implications are massive."

ETEC affects millions of adults and children across the globe, mainly in southern hemisphere countries throughout Africa and South America. It also poses a risk to U.S. troops serving in southern Asia and the Middle East.

Saeed's breakthrough was discovering a way to overcome the miniscule molecular size of one of the illness-inducing toxins produced by the E. coli bug. Since the toxin was so small, it did not prompt the body's defense system to develop immunity, allowing the same individual to repeatedly get sick, often with more severe health implications.

Saeed created a biological carrier to attach to the toxin that once introduced into the body induces a strong . This was done by mapping the toxin's biology and structure during the design of the vaccine.

After creating the carrier in a lab at MSU, Saeed and his team tested it on mice and found the biological activity of the toxin was enhanced by more than 40 percent, leading to its recognition by the body's immune system. After immunizing a group of 10 rabbits, the vaccine led to the production of the highest neutralizing antibody ever reported for this type of the toxin.

Saeed hopes that human clinical trials could begin late in the year.

There also are several other human health implications for the vaccine, besides providing immunity against most E. coli disease, according to Saeed. Many patients who undergo anesthesia during a medical procedure surgery suffer from post-operative paralytic ileus, or an inability to have a bowel movement. A small oral dosage of the vaccine could act as a laxative, which often aren't prescribed after a surgery for fear of side effects, Saeed said. A small dose also could help with urinary retention.

The vaccine will be available for animals as well, Saeed added. He pointed out the E. coli bug also is a major cause of sickness and death for newborn animals such as calves and piglets, which in the United States alone causes $300 million in loss of agricultural products each year.

Saeed's work was funded in part by a $510,000 grant from the National Institutes of Health.

Source: Michigan State University (news : web)

Explore further: Team identifies possible bacterial drivers of inflammatory bowel diseases

add to favorites email to friend print save as pdf

Related Stories

Researcher uncovers treatment for E.coli

Oct 29, 2008

(PhysOrg.com) -- It couldn't be more ironic. Just as the number of people in North Bay, Ont., made ill by a recent E.coli outbreak, topped 200, a University of Alberta professor has announced a breakthrough in development ...

AIDS vaccine nears human testing

Aug 31, 2006

A University of Kansas Medical Center researcher hopes to get the funds needed for the next step in developing his AIDS vaccine -- testing on humans.

AIDS Vaccine Progress Published in Virology

Sep 06, 2006

A University of Kansas School of Medicine researcher’s success developing an AIDS vaccine was reported in the August issue of the peer-reviewed journal Virology. Opendra Narayan, DVM, PhD, and his collaborators have succes ...

Recommended for you

How Alzheimer's peptides shut down cellular powerhouses

10 hours ago

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments : 3

Adjust slider to filter visible comments by rank

Display comments: newest first

Ashy
3 / 5 (2) Apr 15, 2009
If there were not poisoning, diarrhea ends for a week without any help. They only should drink a lot of clear water. Without E. coli human can't do gastrointestinal digestion. This researcher should do something really needing, for example make cheap clearing water system.
Icester
not rated yet Apr 15, 2009
Sorry to disappoint you Ashy... but researchers have different areas of expertise. Einstein was brilliant, but only in his field - don't expect him to make contributions in biology!

Any contribution is a good thing. Sometimes the benefits aren't immediate, but it does help advance the field of science which leads to other, more readily accessible and beneficial contributions.

This is some great work and shouldn't be discounted in any way.
Ashy
1 / 5 (1) Apr 15, 2009
Biologist can find bacteriophage to clear water from bacterias, can't he? He can find harmless for human and easy growing bacteriophage, it will be good method to decrease diarrhea.